Search

Filters

Clear Filters
5:44 PM - 5:50 PM PT

1107 - Irradiated Tumor Cell-Derived Extracellular Vesicles Foster Immunosuppressive Macrophages Formation to Promote Esophageal Squamous Cell Carcinoma Progression
Speaker: Yang, Xi, MD, PhD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
8:05 AM - 8:10 AM PT

1108 - Short-Term Radiotherapy plus Chemotherapy Increased the T Downstaging Rates Compared to Long-Term Chemoradiotherapy in Low-Lying Locally Advanced Rectal Cancer: A Post-Hoc Analysis of the STELLAR Trial
Speaker: Lei, Junqin, MD - ShenZhen Cancer Hospital, ShenZhen, Guangdong
8:10 AM - 8:15 AM PT

1109 - Radiotherapy followed by Systemic Therapy and Tislelizumab in MSS Rectal Cancer with Unresectable Metastases: Results of the MIRACLE-2 Study
Speaker: Zhang, Zhen, MD, PhD - Fudan University Shanghai Cancer Center, shanghai, shanghai
3:10 PM - 3:20 PM PT

111 - Perioperative Chemotherapy Duration Affects the Survival of Locally Advanced Rectal Cancer: A Post-Hoc Analysis of a Multicenter Randomized, Phase III Trial
Speaker: Xu, Tongzhen, MD - Cancer Hospital, Chinese Academy of Medical Science, Bejing, Beijing
8:15 AM - 8:20 AM PT

1110 - Genetic Variants and Immunotherapy-Combined Modality Correlates with Neoadjuvant Therapy Outcomes in Microsatellite-Stable Rectal Cancer
Speaker: Zhang, Zhen, MD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
8:20 AM - 8:25 AM PT

1111 - Peripheral Blood Immune Cell Dynamics as Indicators and Predictors of Clinical Response to Immunotherapy Based Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Speaker: Wang, Yaqi, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai
8:25 AM - 8:30 AM PT

1112 - Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
Speaker: Xu, Yujin, MD, PhD - Zhejiang Cancer Hospital, Hangzhou, Zhejiang
8:30 AM - 8:35 AM PT

1113 - Endoscopic Ultrasound Fine Needle Injection of NBTXR3 Activated by Radiotherapy with Concurrent Chemotherapy for Adenocarcinoma of the Esophagus: Feasibility and Safety of the Phase I Dose Escalation Part for the Photon-Based Cohort
Speaker: Lin, Steven, MD, PhD, FASTRO - The University of Texas MD Anderson Cancer Center, Houston, Texas
8:05 AM - 8:10 AM PT

1114 - Germline Indicators of Radiation Therapy Response in Both Aggressive and Non-Aggressive Prostate Cancer Subtypes
Speaker: Miyamoto, David, MD, PhD - Massachusetts General Hospital, Boston, MA
8:10 AM - 8:15 AM PT

1115 - Prognostic Value of Quantitative Imaging Metrics Obtained in Routine Clinical Practice in a Cohort of Patients Treated with PSMA-RLT
Speaker: Floberg, John, MD, PhD - University of Wisconsin School of Medicine and Public Health, Madison, WI
8:15 AM - 8:20 AM PT

1116 - Discordance of Adverse Molecular Features between the 22-Gene Genomic Classifier Score, Histologic Grade, and NCCN Risk Groups: Analysis of Over 200,000 Patients
Speaker: Jia, Angela, MD, PhD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH
8:20 AM - 8:25 AM PT

1117 - Validation of a Prognostic Multimodal Artificial Intelligence (MMAI) Model in Asian Prostate Cancer (PCa) Patients (pts) from Singapore
Speaker: Chua, Melvin Lee Kiang, MD, PhD - National Cancer Centre Singapore, Singapore, NA